Dae Gon Ha
Stock Analyst at Stifel
(2.50)
# 2,339
Out of 5,147 analysts
55
Total ratings
37.78%
Success rate
5.78%
Average return
Main Sectors:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $98 → $125 | $92.29 | +35.44% | 6 | Feb 26, 2026 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $5.12 | +290.63% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $2.20 | +36.36% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $39.07 | +89.40% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $8.38 | -64.20% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $13.78 | +364.44% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $275.64 | -20.19% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $23.39 | +442.97% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $5.01 | +858.08% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $4.62 | +289.61% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $1.82 | +284.62% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $86 → $52 | $10.22 | +408.81% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $92.73 | -73.04% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $14.37 | +11.34% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $27.80 | +925.18% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.59 | +1,157.86% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.57 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $20.96 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $8.75 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.92 | +1,204.35% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $20.99 | +2,234.44% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $98 → $125
Current: $92.29
Upside: +35.44%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $5.12
Upside: +290.63%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $2.20
Upside: +36.36%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $39.07
Upside: +89.40%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $8.38
Upside: -64.20%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $13.78
Upside: +364.44%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $275.64
Upside: -20.19%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $23.39
Upside: +442.97%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $5.01
Upside: +858.08%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $4.62
Upside: +289.61%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $1.82
Upside: +284.62%
Aug 10, 2022
Downgrades: Hold
Price Target: $86 → $52
Current: $10.22
Upside: +408.81%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $92.73
Upside: -73.04%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $14.37
Upside: +11.34%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $27.80
Upside: +925.18%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.59
Upside: +1,157.86%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.57
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $20.96
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $8.75
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $0.92
Upside: +1,204.35%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $20.99
Upside: +2,234.44%